Introduction
asthma
ASYMPTOMATIC COVID-19, CORONAVIRUS DISEASE 2019, ASTHMA, TYPE 2 DIABETES
Over two years have passed since the Coronavirus disease 2019 (COVID-19) pandemic was declared, and significant efforts to scale up vaccine manufacturing have enabled a step forward in reshaping vaccine distribution. The updated WHO global vaccination strategy to achieve the target of 70% of total population coverage requires vaccination coverage to be extended from a higher to a lower priority group, represented by young people under the age of 18 years (Although children and adolescents are known to have a lower incidence of severe COVID-19, underlying health comorbidities (type 2 diabetes, severe asthma, immunocompromising conditions, and others) have been shown to increase mortality approximately by 10-fold compared to healthy individuals (The Gam-COVID-Vac (Sputnik V) adenoviral-based COVID-19 vaccine was developed at the Gamaleya Centre in 2020. Phase 1–3 clinical trials of Gam-COVID-Vac in adult volunteers (18+ years) have demonstrated a good safety profile, high immunogenicity, and over 91% efficacy in preventing symptomatic COVID-19 as early as 3 weeks after the first vaccination (